Upsher Smith Company Profile
✉ Email this page to a colleague
What is the competitive landscape for UPSHER SMITH, and when can generic versions of UPSHER SMITH drugs launch?
UPSHER SMITH has ninety-nine approved drugs.
There are eight US patents protecting UPSHER SMITH drugs.
There are seventeen patent family members on UPSHER SMITH drugs in ten countries and one hundred and forty-five supplementary protection certificates in fourteen countries.
Summary for Upsher Smith
| International Patents: | 17 |
| US Patents: | 8 |
| Tradenames: | 75 |
| Ingredients: | 69 |
| NDAs: | 99 |
Drugs and US Patents for Upsher Smith
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upsher Smith Labs | CIMETIDINE | cimetidine | TABLET;ORAL | 074506-001 | Jan 24, 1996 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Upsher Smith Labs | FOSINOPRIL SODIUM | fosinopril sodium | TABLET;ORAL | 076188-001 | Oct 8, 2004 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Upsher Smith Labs | JANTOVEN | warfarin sodium | TABLET;ORAL | 040416-007 | Oct 2, 2003 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Upsher Smith Labs | MIRTAZAPINE | mirtazapine | TABLET;ORAL | 076189-003 | Jun 19, 2003 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Upsher Smith Labs | PACERONE | amiodarone hydrochloride | TABLET;ORAL | 075135-003 | Jul 2, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Upsher Smith Labs | KLOR-CON | potassium chloride | CAPSULE, EXTENDED RELEASE;ORAL | 203106-002 | Jul 10, 2015 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Upsher Smith Labs | ZONISAMIDE | zonisamide | CAPSULE;ORAL | 077644-002 | Dec 22, 2005 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Upsher Smith
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Upsher Smith Labs | FORTICAL | calcitonin salmon recombinant | SPRAY, METERED;NASAL | 021406-001 | Aug 12, 2005 | 6,440,392 | ⤷ Sign Up |
| Upsher Smith Labs | FORTICAL | calcitonin salmon recombinant | SPRAY, METERED;NASAL | 021406-001 | Aug 12, 2005 | RE43580 | ⤷ Sign Up |
| Upsher Smith Labs | FORTICAL | calcitonin salmon recombinant | SPRAY, METERED;NASAL | 021406-001 | Aug 12, 2005 | RE40812 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for UPSHER SMITH drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Nasal Spray | 200 IU/spray | ➤ Subscribe | 2006-03-29 |
| ➤ Subscribe | Extended-release Capsules | 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg | ➤ Subscribe | 2015-12-24 |
International Patents for Upsher Smith Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20160124930 | ⤷ Sign Up |
| South Korea | 20150132838 | ⤷ Sign Up |
| Israel | 241053 | ⤷ Sign Up |
| South Korea | 102072618 | ⤷ Sign Up |
| Canada | 2905011 | ⤷ Sign Up |
| Canada | 2857286 | ⤷ Sign Up |
| European Patent Office | 3079703 | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Upsher Smith Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1856135 | CR 2020 00018 | Denmark | ⤷ Sign Up | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113 |
| 0208846 | C990021 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ZALEPLONUM; REGISTRATION NO/DATE: EU/1/99/099/001 - EU/1/99/099/006, EU/1/99/102/001 - EU/1/99/102/006 19990312 |
| 1718641 | 2012/008 | Ireland | ⤷ Sign Up | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209 |
| 2380576 | SPC/GB20/050 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: DEOXYCHOLIC ACID SODIUM SALT; REGISTERED: UK PL 45496/0009 20170526 |
| 2203431 | 15C0013 | France | ⤷ Sign Up | PRODUCT NAME: DASABUVIR OU UN SEL DE CELUI-CI, NOTAMMENT LE SEL DE SODIUM; REGISTRATION NO/DATE: EU/1/14/983 20150119 |
| 2924034 | CR 2019 00024 | Denmark | ⤷ Sign Up | PRODUCT NAME: DORAVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH LAMIVUDINE AND IN COMBINATION WITH TENOFOVIR DISOPROXIL FUMARATE; REG. NO/DATE: EU/1/18/1333 20181126 |
| 1948158 | 1690020-1 | Sweden | ⤷ Sign Up | PRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
